Ventricular arrhythmias in patients with prior aortic valve intervention: Characteristics, ablation and outcomes.


Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
05 2023
Historique:
revised: 19 03 2023
received: 03 10 2022
accepted: 26 03 2023
medline: 22 5 2023
pubmed: 31 3 2023
entrez: 30 3 2023
Statut: ppublish

Résumé

Data regarding ventricular tachycardia (VT) or premature ventricular complex (PVC) ablation in patients with aortic valve (AV) intervention (AVI) is limited. Catheter ablation (CA) can be challenging given perivalvular substrate in the setting of prosthetic valves. We sought to investigate the characteristics, safety, and outcomes of CA in patients with prior AVI and ventricular arrhythmias (VA). We identified consecutive patients with prior AVI (replacement or repair) who underwent CA for VT or PVC between 2013 and 2018. We investigated the mechanism of arrhythmia, ablation approach, perioperative complications, and outcomes. We included 34 patients (88% men, mean age 64 ± 10.4 years, left ventricular (LV) ejection fraction 35.2 ± 15.0%) with prior AVI who underwent CA (22 VT; 12 PVC). LV access was obtained through trans-septal approach in all patients except one patient who had percutaneous transapical access. One patient had combined retrograde aortic and trans-septal approach. Scar-related reentry was the dominant mechanism of induced VTs. Two patients had bundle branch reentry VTs. In the VT group, substrate mapping demonstrated heterogeneous scar that involved the peri-AV area in 95%. Despite that, the site of successful ablation included the periaortic region only in 6 (27%) patients. In the PVC group, signal abnormalities consistent with scar in the periaortic area were noted in 4 (33%) patients. In 8 (67%) patients, the successful site of ablation was unrelated to the periaortic area. No procedure-related complications occurred. The survival and recurrence-free survival rate at 1 year tended to be lower in VT group than in PVC group (p = .06 and p = .05, respectively) with a 1-year recurrence-free survival rate of 52.8% and 91.7%, respectively. No arrhythmia-related death was documented on long-term follow-up. CA of VAs can be performed safely and effectively in patients with prior AVI.

Identifiants

pubmed: 36994918
doi: 10.1111/jce.15896
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1206-1215

Informations de copyright

© 2023 Wiley Periodicals LLC.

Références

Narasimhan C, Jazayeri MR, Sra J, et al. Ventricular tachycardia in valvular heart disease: facilitation of sustained bundle-branch reentry by valve surgery. Circulation. 1997;96(12):4307-4313.
Eckart RE, Hruczkowski TW, Tedrow UB, Koplan BA, Epstein LM, Stevenson WG. Sustained ventricular tachycardia associated with corrective valve surgery. Circulation. 2007;116(18):2005-2011.
Steinberg JS, Gaur A, Sciacca R, Tan E. New-onset sustained ventricular tachycardia after cardiac surgery. Circulation. 1999;99(7):903-908.
Shahim B, Malaisrie SC, George I, et al. Postoperative atrial fibrillation or flutter following transcatheter or surgical aortic valve replacement. JACC. 2021;14(14):1565-1574.
Yeung-Lai-Wah JA, Qi A, McNeill E, et al. New-onset sustained ventricular tachycardia and fibrillation early after cardiac operations. Ann Thorac Surg. 2004;77(6):2083-2088.
Smith R, Grossman W, Johnson L, Segal H, Collins J, Dalen J. Arrhythmias following cardiac valve replacement. Circulation. 1972;45(5):1018-1023.
Marchenese K, Schenk E. Atrioventricular conduction system lesion following cardiac valve replacement. Circulation. 1972;45(suppl II):II 188.
Fedgchin B, Pavri BB, Greenspon AJ, Ho RT. Unique self-perpetuating cycle of atrioventricular block and phase IV bundle branch block in a patient with bundle branch reentrant tachycardia. Heart Rhythm. 2004;1(4):493-496.
Liang JJ, Castro SA, Muser D, et al. Electrophysiologic substrate, safety, procedural approaches, and outcomes of catheter ablation for ventricular tachycardia in patients after aortic valve replacement. JACC. 2019;5(1):28-38.
Khalil F, Siontis K, Bagameri G, Killu AM. Hybrid catheter-based and surgical techniques for ablation of ventricular arrhythmias. Arrhythm Electrophysiol Rev. 2020;9(2):97-103.
Mizuno H, Vergara P, Maccabelli G, et al. Contact force monitoring for cardiac mapping in patients with ventricular tachycardia. J Cardiovasc Electrophysiol. 2013;24(5):519-524.
Killu AM, Ebrille E, Asirvatham SJ, et al. Percutaneous epicardial access for mapping and ablation is feasible in patients with prior cardiac surgery, including coronary bypass surgery. Circulation. 2015;8(1):94-101.
Konecny T, Friedman PA, Sanon S, Rihal CS, Mulpuru SK. Percutaneous transapical access with closure for ventricular tachycardia ablation. Circulation. 2015;8(2):508-511.
Shinoda Y, Komatsu Y, Sekiguchi Y, Nogami A, Aonuma K, Ieda M. Iatrogenic aortic reg\urgitation after radiofrequency ablation of idiopathic ventricular arrhythmias originating from the aortic valvular region. Heart Rhythm. 2019;16(8):1189-1195.
Chung F-P, Lin C-Y, Lin Y-J, et al. Ventricular arrhythmias in nonischemic cardiomyopathy. J Arrhythm. 2018;34(4):336-346.
Shirai Y, Liang JJ, Santangeli P, et al. Comparison of the ventricular tachycardia circuit between patients with ischemic and nonischemic cardiomyopathies. Circulation. 2019;12(7):e007249.
Nakajima I, Narui R, Aboud AA, et al. Periaortic ventricular tachycardias in nonischemic cardiomyopathy: substrate and electrocardiographic correlations. Circulation. 2021;14(2):e008887.

Auteurs

Fouad Khalil (F)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Takumi Toya (T)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Ali Ahmad (A)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Konstantinos C Siontis (KC)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Siva K Mulpuru (SK)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Freddy Del-Carpio Munoz (F)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Yong-Mei Cha (YM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Paul A Friedman (PA)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Thomas Munger (T)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Samuel J Asirvatham (SJ)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Ammar M Killu (AM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH